Drug Profile


Alternative Names: NSC 63984

Latest Information Update: 11 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OXiGENE
  • Developer National Cancer Institute (USA); Tufts-New England Medical Center
  • Class Antifungals; Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Candidiasis; Chronic myeloid leukaemia; Parasitic infections

Most Recent Events

  • 11 Jun 2002 Discontinued - Phase-I for Acute lymphoblastic leukaemia in USA (unspecified route)
  • 11 Jun 2002 Discontinued - Phase-I for Chronic myeloid leukaemia in USA (unspecified route)
  • 11 Jun 2002 Discontinued - Preclinical for Candidiasis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top